Healthcare
Plus Therapeutics, Inc.(PSTV)
Live Price
Offline$4.20
-2.55% today
1Y Change
-6.67%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $10.00M
- Revenue Growth
- -10.5%
- EPS Growth
- +100.0%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Plus Therapeutics, Inc. (PSTV) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $4.20 and down 6.7% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -10.5%, EPS growth of +100.0%, a dividend yield of 0.0%. What stands out right now is revenue -10.5%, EPS +100.0%, free cash flow -94.8% with operating margin -293.5% and ROIC -317.6%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PSTV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-10.5% vs +7.6% peer median
Operating Margin
Below sector median
-293.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -10.5% and EPS is at +100.0%, with operating margin around -293.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -9.4% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 29, 2026 | โ | -2.1% | -7.0% | โ |
2026 Mar 12, 2026 | -2678.6% | -13.8% | -17.2% | -33.8% |
2025 Oct 30, 2025 | -100.0% | +1.9% | -3.8% | +15.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSTV
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PSTV Max Drawdown
-86.88%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PSTV and SPY.
Company Overview
Plus Therapeutics, Inc.
NASDAQ Capital Market
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
- Leadership
- Marc H. Hedrick
- IPO Date
- Jul 11, 2001
- Employees
- 21
- Street Address
- 4200 Marathon Boulevard
- Mailing
- Austin, TX, 78756
- Region
- Austin, TX, US
- Reporting Currency
- USD
- Investor Line
- 737 255 7194
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.8
- Price/Book
- 4.7
Growth
- Revenue
- -10.5%
- EPS
- +100.0%
- Free Cash Flow
- -94.8%
Profitability
- Gross Margin
- 91.5%
- Operating Margin
- -293.5%
- Net Margin
- -429.4%
- ROE
- 774.8%
- ROIC
- -317.6%
Balance Sheet
- Debt/Equity
- 0.21
- Current Ratio
- 1.23
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.